HealthLynked: AI, Interoperability, and a National Policy Tailwind Converge

Why This Moment May Be a Defining Inflection Point for HLYK Investors

Free Healthcare App Poised to Be a Big Money Maker
 

As the U.S. healthcare system undergoes one of the most profound transformations in its history—driven by interoperability mandates, AI adoption, and payer pressure to reduce cost—few companies are positioned as strategically or as comprehensively as HealthLynked (HLYK: OTC).

​

And even fewer have a founder with a proven multi-billion-dollar track record.

​

Dr. Michael Dent, founder of the $1.5B–$5B genomics powerhouse NeoGenomics (NEO: NASD), is now executing an even larger vision: a nationwide, AI-enabled patient and provider network designed to simplify healthcare, unify fragmented records, and dramatically reduce administrative waste.

​

Today’s Board announcement amplifies this momentum at the exact moment federal policy is accelerating AI-enabled healthcare modernization.

​

The Federal Genesis Mission: A Massive National Tailwind for AI-Driven Healthcare

​

On November 24, 2025, the White House formally launched the Genesis Mission, a sweeping national initiative to fuse federal scientific datasets with advanced AI, high-performance computing, and next-generation modeling to accelerate breakthroughs in healthcare, biotech, and scientific discovery.

​

Official White House link:

https://www.whitehouse.gov/presidential-actions/2025/11/launching-the-genesis-mission/

 

The mission directs federal agencies and DOE national labs to modernize health data infrastructure and accelerate AI deployment across the healthcare ecosystem.

​

For investors, the Genesis Mission creates a rare macro-tailwind:

It validates and accelerates the exact categories where HealthLynked already operates — AI-guided care, interoperability, and large-scale digital patient engagement.

​

A Board Built for Scale: Chris Pulos of Marsh McLennan Joins HealthLynked

​

HealthLynked has appointed Chris Pulos, a senior executive with Marsh McLennan, the world’s leading insurance, risk management, and employer benefits advisory firm. Marsh McLennan serves over 95% of the Fortune 100, touching virtually every major payer, employer, and healthcare delivery system in the country.

​

This appointment is a material governance enhancement and a catalyst for HealthLynked’s growth strategy.

​

Why Chris Pulos Matters to HealthLynked’s Next Phase

​

Marsh McLennan is globally recognized for:

• Deep influence across health insurance, employer benefits, and large self-funded groups

• National-scale healthcare cost containment strategies

• Risk management and digital transformation initiatives

• Advisory relationships with major payers, ACOs, TPAs, and employer groups

• Leadership in aligning employers with innovative digital health tools and AI-powered technologies

• ​

Chris Pulos brings a powerful combination of:

• Access to Marsh McLennan’s nationwide client base

• Strategic insight into healthcare cost drivers and payer adoption cycles

• Experience aligning innovative technologies with employer and insurer needs

• National and institutional credibility

• ​

Dr. Dent describes his appointment as:

“A strategic accelerant at exactly the right moment. Chris brings the experience, credibility, and national relationships required for HealthLynked’s transition into an enterprise-grade healthcare platform.”

​

Pulos adds:

​

“HealthLynked’s mission to simplify healthcare and its AI-driven platform align directly with what employers, payers, and providers are demanding. I’m excited to help scale a platform that can materially reduce cost and improve care coordination nationwide.”

This is not a traditional Board addition — it is a force-multiplier designed to support payer adoption, employer integration, and HealthLynked’s transformation into a national infrastructure layer for digital health.

 

Strengthening Governance for National Expansion — and for NASDAQ

Chris Pulos’ appointment aligns perfectly with HealthLynked’s strategic priorities:

• Large-scale employer and insurer partnerships

• Broader digital health adoption across enterprise networks

• AI-enabled care coordination through ARI

• National modernization initiatives under the Genesis Mission

• Strengthened governance for upcoming NASDAQ Capital Markets listing

 

This Board evolution lowers execution risk and increases institutional readiness — two key inputs investors consider when evaluating uplisting-stage companies.

​

Dr Dent’s commitment to improving healthcare: Solving the Hardest Problems at Scale

Investors familiar with Dr. Dent’s history recognize the blueprint:

1. Identify systemic bottlenecks

2. Build technology and data systems to solve them

3. Scale nationally with operational rigor

4. Deliver long-term enterprise value

5. ​

HealthLynked applies this proven playbook to:

• Fragmentation of medical records

• Administrative inefficiency

• Lack of cost transparency

• Poor patient navigation

• Limited payer–provider–patient interoperability

With over one million users and 880,000+ providers, HealthLynked is already building one of the largest consumer-facing health networks in the country.

A Platform Aligned with a Generational Shift

Federal pressure, payer economics, and technology trends are converging:

• Interoperability mandates are reshaping healthcare infrastructure

• AI is becoming essential, not experimental

• The Genesis Mission accelerates national data modernization

• Employers and insurers urgently seek digital efficiencies

• Consumers demand mobile-first healthcare access

HealthLynked offers:

• Unified medical records

• AI-guided navigation (ARI)

• Telehealth and scheduling

• Prescription & procedure savings

• Enterprise tools for payers and providers

This is not incremental innovation — it is infrastructure realignment, and HealthLynked sits squarely at its center.

Why This Moment Is Pivotal

The synergy of:

• A Marsh McLennan executive joining the Board

• Federal AI acceleration through the Genesis Mission

• A ready-to-scale AI platform (ARI)

• A national provider and patient network

• A pending NASDAQ uplisting

…creates a rare and time-sensitive opportunity for investors.

Revenue Acceleration: Multiple High-Margin Channels Ready to Scale

With Chris Pulos joining the Board, HealthLynked gains not only governance strength but direct strategic access to the types of employers and insurers who most benefit from HealthLynked’s offering.

Revenue channels include:

1. Enterprise & Payer Contracts

Six- to seven-figure ARR opportunities across digital intake, interoperability, and AI triage.

2. ARI: A SaaS-Margin AI Engine

Subscription revenue from employers, payers, and clinical partners.

3. Mandate-Driven Adoption

Federal interoperability rules + Genesis Mission momentum shorten sales cycles.

4. Provider Network Monetization

Increasing appointment volume and telehealth engagement.

5. Savings Programs

Recurring and transactional revenue tied directly to patient usage.

Investor Thesis: Why HLYK May Be Undervalued at This Stage

1. HealthLynked sits in front of a $4.5T market with unprecedented AI tailwinds.

The Genesis Mission further legitimizes AI-enabled healthcare modernization.

2. A Marsh McLennan executive brings national distribution reach.

A major credibility event for insurers, employer groups, and capital markets.

3. A NASDAQ uplist may serve as a valuation catalyst.

Micro-cap uplists historically lead to substantial re-ratings.

4. A founder with a multi-billion-dollar track record.

Dent has built national-scale health infrastructure before.

5. Multiple revenue triggers are approaching simultaneously.

6. Timing is ideal: policy, economics, and technology are aligned.

For investors seeking exposure to a high-growth, AI-enabled healthcare platform positioned at the intersection of national policy, enterprise modernization, and capital markets expansion, HealthLynked may represent one of the most asymmetric opportunities in the digital health sector.

As always, individuals should conduct their own due diligence.

​

​

Legal Disclosures and Disclaimers

Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.

​

Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.

​

Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.

​

Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.

​

Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from.​ Green Planet Microcaps was compensated for this article and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.

​

Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.